Emmaus has entered into a distribution agreement with Cardinal Health that will make Endari (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older, available nationwide to pharmacies that utilize Cardinal as their distributor. Cardinal Health connects patients, providers, payers, pharmacists, and manufacturers for integrated care coordination and better patient management.
Since launching Endari, the first FDA approved sickle cell treatment in 20 years, Emmaus has brought this therapy to patients in 36 states, Washington DC, and Puerto Rico. In addition to the distributors already in place, this agreement with Cardinal will further broaden Endari’s distribution, with the potential to reach many more patients suffering from the acute complications associated with sickle cell disease, such as pain and frequent hospitalizations.
“Partnering with Cardinal demonstrates the growing demand for Endari by physicians and patients alike,” said Yutaka Niihara, MD, MPH, CEO and chairman of Emmaus. “Teaming up with Cardinal solidifies our growing distribution network in the United States.”
(Source: Emmaus Life Sciences, Inc.)
